Cost-Utility Analysis of Erlotib Versus Standard Chemotherapy in First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1614
https://www.valueinhealthjournal.com/article/S1098-3015(16)01682-X/fulltext
Section Title :
Cancer - Cost Studies
Section Order :
336
First Page :
A154
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01682-X&doi=10.1016/j.jval.2016.03.1614